| Liu, Haiyan |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT05754736: Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations. |
|
|
| Recruiting | 2 | 50 | RoW | Ametinib combined with bevacizumab, Third-generation TKI combined with antivascular targeting drug | The Second Affiliated Hospital of Shandong First Medical University | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT05170594: A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Bevacizumab, Antiangiogenic drugs, chemotherapy, Non-platinum chemotherapy, Fluzoparib, PARPi | The Second Affiliated Hospital of Shandong First Medical University | Ovarian Cancer | 06/24 | 06/24 | | |
NCT06730373: First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) |
|
|
| Recruiting | 2 | 110 | RoW | Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin, Capecitabine, 5-FU, Cisplatin | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma | 12/26 | 12/27 | | |
NCT05170581: Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Sintilimab Combined with Platinum-containing Chemotherapy, PD-1 inhibitor combined with chemotherapy | The Second Affiliated Hospital of Shandong First Medical University | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
NCT05184946: Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 72 | RoW | Camrelizumab Combined with SOX, Anti-PD1 Combine with chemotherapy | The Second Affiliated Hospital of Shandong First Medical University | Gastric Cancer | 10/25 | 10/25 | | |
NCT06092242: The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Tas-102(Suyuan) combined with bevacizumab | The Second Affiliated Hospital of Shandong First Medical University | Colorectal Cancer | 10/25 | 10/27 | | |
NCT05166837: The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects |
|
|
| Completed | 1 | 52 | RoW | STSA-1002 injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Healthy | 01/23 | 01/23 | | |
TQB2858-Ⅰ-06, NCT05068921: A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy |
|
|
| Recruiting | 1 | 40 | RoW | TQB2858 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cervical Cancer | 05/23 | 07/23 | | |
| Liu, Zimin |
KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension |
|
|
| Active, not recruiting | 3 | 120 | RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN® | Merck Sharp & Dohme LLC | Gastric Cancer, Gastroesophageal Junction Cancer | 02/24 | 04/25 | | |
NCT06730373: First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) |
|
|
| Recruiting | 2 | 110 | RoW | Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin, Capecitabine, 5-FU, Cisplatin | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma | 12/26 | 12/27 | | |
RCTS, NCT05586061: First-line Treatment With RC48 Plus Tislelizumab and S-1() in Advanced Gastric Cancer |
|
|
| Active, not recruiting | 2 | 55 | RoW | Disitamab vedotin, RC48, Tislelizumab, BGB-A317, S1 | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer | 12/24 | 12/24 | | |
NCT05585580: Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy |
|
|
| Recruiting | 2 | 59 | RoW | Serplulimab, Lenvatinib, Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome | Qilu Hospital of Shandong University | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | 11/25 | 11/26 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 12/25 | 12/25 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT04835324: Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study |
|
|
| Active, not recruiting | N/A | 650 | RoW | | Chinese Academy of Medical Sciences, Beijing Hospital, Jiangsu Cancer Institute & Hospital, The Affiliated Hospital of Qingdao University, Shanxi Province Cancer Hospital, Affiliated Hospital of Hebei University, Shandong Cancer Hospital and Institute, The First Affiliated Hospital of Zhengzhou University, Hebei Medical University Fourth Hospital, First Hospital of China Medical University | Advanced Colorectal Cancer | 02/22 | 10/22 | | |
NCT06157216: Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer |
|
|
| Active, not recruiting | N/A | 85 | RoW | MRD-guided therapy | Qilu Hospital of Shandong University, Shandong Provincial Hospital, Jinan Central Hospital, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University | Stage II-III Gastric Cancer | 04/27 | 04/29 | | |
NCT06609759: Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer |
|
|
| Recruiting | N/A | 197 | RoW | Standard chemotherapy regimen | Qilu Hospital of Shandong University, Shandong Provincial Hospital, Jinan Central Hospital, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University | Stage II-III Gastric Cancer | 01/28 | 01/29 | | |
| Recruiting | N/A | 190 | RoW | | Peking University Cancer Hospital & Institute | DMMR Cancer, MSI-H, Solid Tumor | 02/26 | 02/26 | | |
| Li, Xianqi |
NCT06685978: Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands |
|
|
| Recruiting | 3 | 430 | RoW | Xiang Ju Ru Pi Ning capsule Placebo, Placebo group, Xiang Ju Ru Pi Ning capsule, Experimental group | Tasly Pharmaceutical Group Co., Ltd | Hyperplasia of Mammary Glands | 04/26 | 07/26 | | |
